Milestone Scientific Inc

Milestone Scientific Inc(MLSS)の株式分析

$0.302

+0.003 (+0.97%)終値時点

Loading chart…
高値
0.329
始値
0.310
出来高加重平均価格
0.31
出来高
90.06K
時価総額
52.51M
安値
0.300
売買代金
27.95K
EV/EBITDA(TTM)
-6.33

Milestone Scientific Inc. is a biomedical technology company. The Company patents, designs, develops and commercializes diagnostic and therapeutic injection technologies and devices for medical and dental use. The Company operates through two segments: dental and medical. The Company has developed a computer-controlled anesthetic delivery device, its DPS Dynamic Pressure Sensing Technology System, to meet the needs of various subcutaneous drug delivery injections and fluid aspiration. Its device, using The Wand, a single-use disposable handpiece, is marketed in dentistry under the trademarks CompuDent and STA Single Tooth Anesthesia System, and is suitable for all dental procedures that require local anesthetic. The dental devices are sold in the United States, Canada and in over 41 other countries. In addition, the Company has obtained CE mark approval for certain medical devices, which can be marketed and sold in various European countries.

AI分析 of Milestone Scientific Inc (MLSS)

中立

Milestone Scientific Inc is currently trading at $0.302, which is significantly below its 52-week high of $0.58, indicating potential for recovery. However, the RSI is at 42.26, suggesting the stock is neither overbought nor oversold, and the forward P/E ratio is 18.21, indicating that the stock may be overvalued based on future earnings expectations. The company has shown revenue growth of 22% year-over-year in Q2 2026, but it still faces challenges with declining gross margins and negative net income, which was -$1,059,332 in Q2 2026. The main risk is the declining gross margin, which fell to 66.55% in Q2 2026, indicating increasing costs that could impact profitability.

アナリスト評価(1)

上値余地 +231.13%
買い
1 買い
0 中立
0 売り
現在: 0.30
安値
1.00
平均
1.00
高値
1.00

Benchmark

2025-11-20

目標株価

$1

Speculative Buy

Benchmark

2024-11-20

目標株価

$1.25

買い

Benchmark

2024-10-10

目標株価

$1.25

買い

バリュエーション指標

Milestone Scientific Inc(MLSS)の現在の予想PERは18.21で、5年平均は-8.67です。

予想PER

割高
5年平均 P/E
-8.67
現在のP/E
18.21
割高
4.93
割安
-22.27

予想EV/EBITDA

割安
5年平均 EV/EBITDA
-1.14
現在のEV/EBITDA
-6.33
割高
1.51
割安
-3.79

予想PSR

割安
5年平均 P/S
5.64
現在のP/S
2.39
割高
8.30
割安
2.98

Alphio AI による MLSS の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%MLSS

$0.99

シナリオ価格

基

基本

基本 · 50%MLSS

$0.88

シナリオ価格

弱

弱気

弱気 · 25%MLSS

$0.85

シナリオ価格

イベントタイムライン

2026-09-29 (ET)

09:30:00

Milestone Scientific Drives Growth in CompuFlo Medical Business

2026-09-08 (ET)

17:30:00

Milestone Scientific Files $45M Mixed Securities Shelf

2026-07-01 (ET)

12:00:00

Markets Mixed as Semiconductor Stocks Slip

09:30:00

Company Reports 300% Revenue Growth in Q2

2026-05-14 (ET)

16:30:00

Dow Rises 370 Points as Markets Optimistic on US-China Talks

ニュース

MLSS のよくある質問 — Alphio AI が回答

Milestone Scientific Inc. is a biomedical technology company. The Company patents, designs, develops and commercializes diagnostic and therapeutic injection technologies and devices for medical and dental use. The Company operates through two segments: dental and medical. The Company has developed a computer-controlled anesthetic delivery device, its DPS Dynamic Pressure Sensing Technology System, to meet the needs of various subcutaneous drug delivery injections and fluid aspiration. Its device, using The Wand, a single-use disposable handpiece, is marketed in dentistry under the trademarks CompuDent and STA Single Tooth Anesthesia System, and is suitable for all dental procedures that require local anesthetic. The dental devices are sold in the United States, Canada and in over 41 other countries. In addition, the Company has obtained CE mark approval for certain medical devices, which can be marketed and sold in various European countries. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).

Milestone Scientific Inc is currently trading at $0.302, which is significantly below its 52-week high of $0.58, indicating potential for recovery. However, the RSI is at 42.26, suggesting the stock is neither overbought nor oversold, and the forward P/E ratio is 18.21, indicating that the stock may be overvalued based on future earnings expectations. The company has shown revenue growth of 22% year-over-year in Q2 2026, but it still faces challenges with declining gross margins and negative net income, which was -$1,059,332 in Q2 2026. The main risk is the declining gross margin, which fell to 66.55% in Q2 2026, indicating increasing costs that could impact profitability.

1 analysts cover MLSS: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 1.00.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

関連記事

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める